Osimertinib Mesylate
FDA-approved product (tablet, oral), marketed as Tagrisso.
- Registered studies
- 26
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Neoplasm
- Non-small cell lung carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
26registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Osimertinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)
NCT05085054 · start 2022-06-01
Registered record
- Registry ID
- NCT05085054
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Osimertinib Mesylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2022-06-01
- Completion
- 2024-08-01
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon Small Cell Lung CancerInterventionOsimertinib MesylatePhasePhase 2Registry statusUnknownTQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer
NCT05284994 · start 2022-03-11
Registered record
- Registry ID
- NCT05284994
- Conditions
- Nonsmall-cell Lung Cancer
- Interventions
- TQ-B3525 Tablets, Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Unknown
- Start
- 2022-03-11
- Completion
- 2024-06
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNonsmall-cell Lung CancerInterventionTQ-B3525 Tablets, Osimertinib Mesylate TabletsPhasePhase 1 / Phase 2Registry statusUnknownSI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05020769 · start 2022-01-06
Registered record
- Registry ID
- NCT05020769
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SI-B001; Osimertinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Active not recruiting
- Start
- 2022-01-06
- Completion
- 2025-12
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung CancerInterventionSI-B001; OsimertinibPhasePhase 2 / Phase 3Registry statusActive not recruitingEfficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
NCT05132777 · start 2021-11-20
Registered record
- Registry ID
- NCT05132777
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations
- Interventions
- JMT101; Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2021-11-20
- Completion
- 2024-09-30
- Enrolment
- 155
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLocally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion MutationsInterventionJMT101; Osimertinib Mesylate TabletsPhasePhase 2Registry statusUnknownStudy of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
NCT06525246 · start 2021-08-06
Registered record
- Registry ID
- NCT06525246
- Conditions
- Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Recurrent Non-Small Cell Lung Cancer; EGFR Mutation-Related Tumors
- Interventions
- ONO-7475; Osimertinib Mesylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-08-06
- Completion
- 2025-06-23
- Enrolment
- 78
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStage IIIB Non-small Cell Lung Cancer; Stage IIIC Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Recurrent Non-Small Cell Lung Cancer +1 moreInterventionONO-7475; Osimertinib MesylatePhasePhase 1Registry statusCompletedA Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers
NCT04798638 · start 2021-04-30
Registered record
- Registry ID
- NCT04798638
- Conditions
- Healthy Volunteers
- Interventions
- TY-9591 Tablets under Fasted Condition - Arm1; Osimertinib Mesylate Tablets under Fasted Condition - Arm1; TY-9591 Tablets after a High-fat Meal - Arm1; Osimertinib Mesylate Tablets under Fasted Condition - Arm2; TY-9591 Tablets under Fasted Condition - Arm2; TY-9591 Tablets after a High-fat Meal - Arm2
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-04-30
- Completion
- 2021-09-09
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionTY-9591 Tablets under Fasted Condition - Arm1; Osimertinib Mesylate Tablets under Fasted Condition - Arm1; TY-9591 Tablets after a High-fat Meal - Arm1; Osimertinib Mesylate Tablets under Fasted Condition - Arm2 +2 morePhasePhase 1Registry statusCompletedOsimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
NCT04438902 · start 2020-12-12
Registered record
- Registry ID
- NCT04438902
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- osimertinib mesylate tablets and anlotinib hydrochloride capsules
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2020-12-12
- Completion
- 2023-02-16
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon Small Cell Lung CancerInterventionosimertinib mesylate tablets and anlotinib hydrochloride capsulesPhasePhase 2Registry statusTerminatedA Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
NCT04001777 · start 2019-07-04
Registered record
- Registry ID
- NCT04001777
- Conditions
- EGFR Positive Non-small Cell Lung Cancer
- Interventions
- APG-1252; Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2019-07-04
- Completion
- 2026-06
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEGFR Positive Non-small Cell Lung CancerInterventionAPG-1252; Osimertinib Mesylate TabletsPhasePhase 1Registry statusActive not recruitingOsimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
NCT03460275 · start 2018-02-26
Registered record
- Registry ID
- NCT03460275
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2018-02-26
- Completion
- 2020-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung CancerInterventionOsimertinib Mesylate TabletsPhasePhase 2Registry statusUnknownApatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
NCT03050411 · start 2016-05
Registered record
- Registry ID
- NCT03050411
- Conditions
- Nonsmall Cell Lung Cancer
- Interventions
- Apatinib Mesylate Tablets; EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2016-05
- Completion
- 2019-10
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNonsmall Cell Lung CancerInterventionApatinib Mesylate Tablets; EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)PhasePhase 1Registry statusUnknownTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060 · start 2015-08-17
Registered record
- Registry ID
- NCT02465060
- Conditions
- Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
- Interventions
- Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2015-08-17
- Completion
- 2026-12-31
- Enrolment
- 6,452
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 moreInterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 morePhasePhase 2Registry statusActive not recruiting